Browse through our press and news section by category:

29.10.2015, Mainz, Germany / St. Gallen, Switzerland

SCHOTT Increases Production of Polymer Syringes by 50 %

Center of Excellence in Switzerland to Ramp up Capacity for SCHOTT TopPac®
SCHOTT is currently expanding the manufacturing capacity for its SCHOTT TopPac® prefillable polymer syringes to address increasing customer demand. The new production line will be installed at the company’s center of excellence for Pre-fillable syringes in St. Gallen, Switzerland. This move will offer a greater degree of flexibility for customers and further strengthen the importance of the Swiss site which focuses on both, glass and polymer syringes.

“The demand for our polymer syringes has increased since customers appreciate the versatile advantages of the material: It’s break resistant and lightweight, yet has a glass-like transparency. And the excellent barrier properties of the SCHOTT TopPac® syringe system keep the drug stable over shelf life”, says Anil-Kumar Busimi, Head of Global Product Management Syringe Business.

The new production line will seamlessly be integrated in SCHOTT’s existing setup which uses advanced technologies. SCHOTT TopPac® syringes are manufactured in clean rooms with a fully automated process starting from injection-molding to the final packaging in nest and tub. The syringes are sterilized and are ready for aseptic filling operations.

Complete Syringe Portfolio

SCHOTT has been manufacturing glass and polymer syringes in Europe since 1996. Today, the production is concentrated in Switzerland and is supported by an R&D team based at the site. From here SCHOTT has developed a complete portfolio of both glass and polymer syringes. This offers pharma companies a broad range of solutions, suitable for a variety of applications like heparin, vaccines, biotech, and special applications such as intensive care.
In the field of glass syringes, the offerings range from 0.5 to 3 Milliliter products marketed under the brand name syriQ®. All glass syringes are available with luer lock, luer cone or with staked needle.

SCHOTT TopPac® polymer syringes, in turn, are available in the range from 1ml to 50ml with cross linked silicone for optimal functionality. In addition, the company has recently introduced an innovative polymer syringe designed to improve the safety of sensitive drugs: the new product named SCHOTT TopPac® SD offers new features for a reduced E&L (extractables and leachables) profile and ensures high drug stability.

syriQ® and SCHOTT TopPac® are registered trademarks of SCHOTT AG.

SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products. SCHOTT is an innovative enabler for many industries, including the home appliance, pharmaceutical, electronics, optics, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. The group maintains a global presence with production sites and sales offices in 35 countries. With its workforce of approximately 15,400 employees, sales of 1.87 billion euros were generated in fiscal year 2013/2014. The parent company, SCHOTT AG, has its headquarters in Mainz (Germany) and is solely owned by the Carl Zeiss Foundation. As a foundation company, SCHOTT assumes special responsibility for its employees, society and the environment.

Press contact
Christina Rettig
Public Relations Manager
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4094
Further information
Salvatore Ruggiero
Vice President Marketing and Communication
Hattenbergstraße 10
55122 Mainz
Phone: +49 6131/66-4140